Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Arcturus Therapeutics Ltd (ARCT)

$10.99 +0.71 (6.91%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	292.19M
Revenue (ttm)	82.03M
Net Income (ttm)	-65.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-80.19%
Debt to Equity Ratio	0.00

Volume	2,293,600
Avg Vol	659,806
Day's Range	N/A - N/A
Shares Out	28.42M
Stochastic %K	90%
Beta	2.39
Analysts	Strong Sell
Price Target	$18.00

Company Profile

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address orni...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 900 2660

Website: arcturusrx.com

Address:

10285 Science Center Drive, San Diego, United States

lecorb Aug. 21 at 4:22 PM

$ARCT EXTREME OVERBUYING!

0 · Reply

Den00 Aug. 21 at 3:53 PM

$MRNA $ARCT great

1 · Reply

Merlintrader Aug. 21 at 3:45 PM

$SLS $BEAM $NTLA $ARCT

0 · Reply

GoCoogs Aug. 21 at 3:23 PM

$ARCT Looking good

0 · Reply

Dr_Feel_Good Aug. 21 at 3:20 PM

$ARCT Happy Friday Fam!!!!

0 · Reply

wahoowa96 Aug. 21 at 3:07 PM

$ARCT Dump Kennedy 🤣 Musk to the president of the United States!

3 · Reply

joetheoxx Aug. 21 at 2:42 PM

$MRNA While $MRNA faces potential royalty payments due to LNP patents, $ARCT has already raked in millions from mRNA vaccines with its LUNAR platform. The speculation: Similar cash flows could now follow for cancer vaccines as well.

0 · Reply

ajmrtxl Aug. 21 at 2:33 PM

$ARCT 's latest squeeze play

0 · Reply

TheRealShortSqueezy Aug. 21 at 2:09 PM

$ARCT 12.31 HIGHS!!

0 · Reply

MaxCorona Aug. 21 at 1:38 PM

$ARCT would become nervous if I had shorted this😂

2 · Reply

Arcturus Therapeutics Holdings Transcript: Canaccord Genuity's 46th Annual Growth Conference

2026-08-07T11:20:59.000Z - 14 days ago

Arcturus Therapeutics price target lowered to $20 from $21 at Canaccord

Aug 6, 2026, 4:30 PM EDT - 14 days ago

Arcturus Therapeutics Holdings Earnings Call Transcript: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 14 days ago

Arcturus Therapeutics Holdings Earnings release: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 14 days ago

Arcturus Therapeutics Holdings Quarterly report: Q2 2026

Aug 6, 2026, 4:01 PM EDT - 14 days ago

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress

Jul 28, 2026, 4:01 PM EDT - 23 days ago

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026

Jul 20, 2026, 4:01 PM EDT - 4 weeks ago

Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

2026-07-02T13:55:29.000Z - 7 weeks ago

Arcturus, Thermo Fisher deal adds support to ARCT-032 exposure, says Roth

TMO

2026-07-02T11:05:59.000Z - 7 weeks ago

Arcturus announces collaboration with Thermo Fisher to advance ARCT-032

TMO

Jul 2, 2026, 7:00 AM EDT - 7 weeks ago

Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis

2026-07-02T09:30:08.000Z - 7 weeks ago

Arcturus Therapeutics initiated with a Buy at Freedom Broker

Jun 30, 2026, 11:01 AM EDT - 7 weeks ago

Arcturus could halve the grid's electrical losses using its nano-infused copper

Jun 4, 2026, 9:20 AM EDT - 2 months ago

Arcturus Therapeutics Holdings Transcript: Jefferies Global Healthcare Conference 2026

May 26, 2026, 4:01 PM EDT - 3 months ago

Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

May 18, 2026, 12:30 PM EDT - 3 months ago

Arcturus Therapeutics Holdings Transcript: 16th Annual LD Micro Invitational Conference

May 7, 2026, 4:30 PM EDT - 3 months ago

Arcturus Therapeutics Holdings Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Arcturus Therapeutics Holdings Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Arcturus Therapeutics Holdings Quarterly report: Q1 2026

May 7, 2026, 4:01 PM EDT - 3 months ago

Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress

Apr 27, 2026, 4:01 PM EDT - 4 months ago

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Arcturus Therapeutics Holdings Proxy statement: Proxy filing

Mar 23, 2026, 12:30 PM EDT - 5 months ago

Arcturus Therapeutics Holdings Transcript: The 38th Annual Roth Conference

2026-03-18T09:05:17.000Z - 5 months ago

Arcturus Therapeutics initiated with a Buy at B. Riley

Mar 11, 2026, 11:20 AM EDT - 5 months ago

Arcturus Therapeutics Holdings Transcript: Leerink Global Healthcare Conference 2026

Mar 5, 2026, 9:00 AM EST - 6 months ago

Arcturus Therapeutics to Attend Upcoming Investor Conference

2026-03-05T11:25:30.000Z - 6 months ago

Arcturus Therapeutics price target lowered to $21 from $66 at Canaccord

2026-03-04T12:55:37.000Z - 6 months ago

Arcturus Therapeutics price target lowered to $25 from $72 at Piper Sandler

2026-03-04T10:50:31.000Z - 6 months ago

Arcturus Therapeutics price target raised to $8 from $7 at Citi

Mar 3, 2026, 4:30 PM EST - 6 months ago

Arcturus Therapeutics Holdings Earnings Call Transcript: Q4 2025

Mar 3, 2026, 4:30 PM EST - 6 months ago

Arcturus Therapeutics Holdings Annual report: Q4 2025

Mar 3, 2026, 4:30 PM EST - 6 months ago

Arcturus Therapeutics Holdings Earnings release: Q4 2025

Mar 3, 2026, 4:01 PM EST - 6 months ago

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress

Feb 17, 2026, 4:01 PM EST - 6 months ago

Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026

Feb 11, 2026, 10:30 AM EST - 6 months ago

Arcturus Therapeutics Holdings Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

2026-01-22T21:10:46.000Z - 7 months ago

Arcturus Therapeutics initiated with a Buy at Roth Capital

Jan 12, 2026, 8:15 PM EST - 7 months ago

Arcturus Therapeutics Holdings Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 8:15 PM EST - 7 months ago

Arcturus Therapeutics Holdings Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 5:30 PM EST - 8 months ago

Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

2026-01-06T11:21:09.000Z - 8 months ago

Arcturus Therapeutics price target lowered to $7 from $9 at Citi

2025-12-30T21:05:16.000Z - 8 months ago

Arcturus Therapeutics files $500M mixed securities shelf

Dec 30, 2025, 7:00 AM EST - 8 months ago

Arcturus Therapeutics Holdings Registration statement: Registration Filing

2025-11-13T11:40:58.000Z - 10 months ago

Arcturus Therapeutics price target lowered to $9 from $12 at Citi

2025-11-11T11:40:12.000Z - 10 months ago

Arcturus Therapeutics price target lowered to $72 from $140 at Piper Sandler

Nov 10, 2025, 4:30 PM EST - 10 months ago

Arcturus Therapeutics Holdings Earnings Call Transcript: Q3 2025

Nov 10, 2025, 4:30 PM EST - 10 months ago

Arcturus Therapeutics Holdings Quarterly report: Q3 2025

Nov 10, 2025, 4:30 PM EST - 10 months ago

Arcturus Therapeutics Holdings Earnings release: Q3 2025

Nov 10, 2025, 4:01 PM EST - 10 months ago

Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress

Nov 4, 2025, 4:01 PM EST - 10 months ago

Arcturus Therapeutics to Attend Upcoming Investor Conferences

Oct 28, 2025, 4:01 PM EDT - 10 months ago

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025

Oct 22, 2025, 8:53 AM EDT - 10 months ago

Arcturus Therapeutics shares plunge 56% after mixed phase 2 CF drug results

Oct 22, 2025, 7:30 AM EDT - 10 months ago

Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program

Aug 11, 2025, 4:30 PM EDT - 1 year ago

Arcturus Therapeutics Holdings Earnings Call Transcript: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 1 year ago

Arcturus Therapeutics Holdings Quarterly report: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 1 year ago

Arcturus Therapeutics Holdings Earnings release: Q2 2025

Aug 11, 2025, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress

Jul 24, 2025, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

Jun 30, 2025, 12:00 PM EDT - 1 year ago

Arcturus Therapeutics Holdings Transcript: Status Update

Jun 30, 2025, 12:00 PM EDT - 1 year ago

Arcturus Therapeutics Holdings Press release: Status Update

Jun 30, 2025, 12:00 PM EDT - 1 year ago

Arcturus Therapeutics Holdings Slides: Status Update

Jun 30, 2025, 11:00 AM EDT - 1 year ago

Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program

Jun 23, 2025, 8:30 AM EDT - 1 year ago

Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency

May 12, 2025, 4:30 PM EDT - 1 year ago

Arcturus Therapeutics Holdings Earnings Call Transcript: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Arcturus Therapeutics Holdings Quarterly report: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Arcturus Therapeutics Holdings Earnings release: Q1 2025

May 12, 2025, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress

May 11, 2025, 6:00 PM EDT - 1 year ago

Arcturus Therapeutics Holdings Slides: Corporate Presentation

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Arcturus Therapeutics Holdings Proxy statement: Proxy Filing

Apr 22, 2025, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025

Apr 16, 2025, 11:00 AM EDT - 1 year ago

Arcturus Therapeutics Holdings Transcript: Status Update

Apr 16, 2025, 11:00 AM EDT - 1 year ago

Arcturus Therapeutics Holdings Slides: Status Update

Apr 11, 2025, 12:00 PM EDT - 1 year ago

Arcturus Therapeutics Holdings Transcript: Fireside Chat

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1

Mar 12, 2025, 10:40 AM EDT - 1 year ago

Arcturus Therapeutics Holdings Transcript: Leerink’s Global Healthcare Conference 2025

Mar 6, 2025, 4:30 PM EST - 1 year ago

Arcturus Therapeutics Holdings Earnings Call Transcript: Q4 2024

Mar 6, 2025, 4:30 PM EST - 1 year ago

Arcturus Therapeutics Holdings Annual report: Q4 2024

Mar 6, 2025, 4:30 PM EST - 1 year ago

Arcturus Therapeutics Holdings Earnings release: Q4 2024

Mar 6, 2025, 4:30 PM EST - 1 year ago

Arcturus Therapeutics Holdings Slides: Q4 2024

Mar 6, 2025, 4:01 PM EST - 1 year ago

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress

Mar 5, 2025, 4:30 PM EST - 1 year ago

Arcturus Therapeutics to Present at Leerink's Global Healthcare Conference 2025

Feb 24, 2025, 4:01 PM EST - 1 year ago

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025

Feb 14, 2025, 8:30 AM EST - 1 year ago

European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

Feb 6, 2025, 10:30 AM EST - 1 year ago

Arcturus Therapeutics Holdings Transcript: Guggenheim SMID Cap Biotech Conference

Feb 4, 2025, 8:30 AM EST - 1 year ago

Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate

Jan 31, 2025, 3:00 AM EST - 1 year ago

Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19

Jan 30, 2025, 4:01 PM EST - 1 year ago

Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference

Jan 15, 2025, 12:45 PM EST - 1 year ago

Arcturus Therapeutics Holdings Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 10, 2025, 8:00 AM EST - 1 year ago

Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial

Jan 6, 2025, 4:01 PM EST - 1 year ago

Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency

Dec 16, 2024, 4:01 PM EST - 1 year ago

Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 3, 2024, 4:30 PM EST - 1 year ago

Arcturus Therapeutics Holdings Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 20, 2024, 4:30 AM EST - 1 year ago

Arcturus Therapeutics Holdings Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 8:00 PM EST - 1 year ago

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

Nov 14, 2024, 1:00 AM EST - 1 year ago

Meiji Seika Pharma Announces Investment in ARCALIS, Inc.

Nov 11, 2024, 4:01 PM EST - 1 year ago

Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial

Nov 7, 2024, 4:30 PM EST - 1 year ago

Arcturus Therapeutics Holdings Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Arcturus Therapeutics Holdings Quarterly report: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Arcturus Therapeutics Holdings Earnings release: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Arcturus Therapeutics Holdings Slides: Q3 2024

Nov 7, 2024, 4:01 PM EST - 1 year ago

Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress

Oct 31, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024

Sep 30, 2024, 8:00 AM EDT - 2 years ago

Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination

Sep 18, 2024, 8:00 AM EDT - 2 years ago

Arcturus Therapeutics Holdings Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 13, 2024, 8:15 AM EDT - 2 years ago

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

Sep 9, 2024, 11:00 AM EDT - 2 years ago

Arcturus Therapeutics Holdings Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 4, 2024, 3:00 PM EDT - 2 years ago

Arcturus Therapeutics Holdings Transcript: 2024 Wells Fargo Healthcare Conference

Sep 3, 2024, 8:30 AM EDT - 2 years ago

Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis

Aug 27, 2024, 5:00 PM EDT - 2 years ago

Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

Aug 13, 2024, 9:30 AM EDT - 2 years ago

Arcturus Therapeutics Holdings Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 5, 2024, 4:30 PM EDT - 2 years ago

Arcturus Therapeutics Holdings Earnings Call Transcript: Q2 2024

Aug 5, 2024, 4:30 PM EDT - 2 years ago

Arcturus Therapeutics Holdings Quarterly report: Q2 2024

Aug 5, 2024, 4:30 PM EDT - 2 years ago

Arcturus Therapeutics Holdings Earnings release: Q2 2024

Aug 5, 2024, 4:30 PM EDT - 2 years ago

Arcturus Therapeutics Holdings Slides: Q2 2024

Aug 5, 2024, 4:01 PM EDT - 2 years ago

Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress

Aug 1, 2024, 4:01 PM EDT - 2 years ago

Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference

Jul 18, 2024, 7:30 PM EDT - 2 years ago

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024

Jul 1, 2024, 4:01 PM EDT - 2 years ago

Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs

Jun 20, 2024, 8:00 AM EDT - 2 years ago

Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors

Jun 7, 2024, 10:30 AM EDT - 2 years ago

Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference

lecorb Aug. 21 at 4:22 PM

$ARCT EXTREME OVERBUYING!

0 · Reply

Den00 Aug. 21 at 3:53 PM

$MRNA $ARCT great

1 · Reply

Merlintrader Aug. 21 at 3:45 PM

$SLS $BEAM $NTLA $ARCT

0 · Reply

GoCoogs Aug. 21 at 3:23 PM

$ARCT Looking good

0 · Reply

Dr_Feel_Good Aug. 21 at 3:20 PM

$ARCT Happy Friday Fam!!!!

0 · Reply

wahoowa96 Aug. 21 at 3:07 PM

$ARCT Dump Kennedy 🤣 Musk to the president of the United States!

3 · Reply

joetheoxx Aug. 21 at 2:42 PM

0 · Reply

ajmrtxl Aug. 21 at 2:33 PM

$ARCT 's latest squeeze play

0 · Reply

TheRealShortSqueezy Aug. 21 at 2:09 PM

$ARCT 12.31 HIGHS!!

0 · Reply

MaxCorona Aug. 21 at 1:38 PM

$ARCT would become nervous if I had shorted this😂

2 · Reply

bigchouse Aug. 21 at 1:34 PM

$ARCT

0 · Reply

Den00 Aug. 21 at 1:28 PM

$ARCT

0 · Reply

bigchouse Aug. 21 at 12:34 PM

$ARCT

2 · Reply

AnomalyDetective Aug. 21 at 12:26 PM

$ARCT breakout continues in the positive Healthcare sector gauges for now up +33.7% for the week and +90.1% on the signal. Credit vmbreakouts.com @vmbreakouts

0 · Reply

King316 Aug. 21 at 10:12 AM

$ARCT CCORF analyst Whitney Ijem maintains $ARCTURUS Therapeutics (ARCT.US)$ with a buy rating, and maintains the target price at $20.

1 · Reply

2PacalypseNow4Life Aug. 21 at 6:53 AM

$ARCT hard 2 believe sion was valued at $50 / share (over 2 bil?!) and arct with all its potential trading around 300 mil right now.

0 · Reply

2PacalypseNow4Life Aug. 21 at 6:28 AM

$ARCT Huge potential: pandemic influenza (h5n1), seasonal influenza, rsv, ebv, arct032 entering phase 3 next year, arct810 after phase 2, entering phase 3 this year i believe. i wouldnt be surprised if we hit $50 this year :]

2 · Reply

Dr_Feel_Good Aug. 21 at 5:42 AM

Dont worry…. about a thing. Because every little thing is going to be alright $MRVL $DRD $ARCT $BITO $FCX 🌊🏄‍♂️

0 · Reply

BigPlaySnipers Aug. 20 at 11:14 PM

TheScanner.Ai I built a sick tool that retail can fish on their own, and not have to follow someone’s every move. $CAST $CAPR $ARCT $TRNR Link in bio

0 · Reply

Merlintrader Aug. 20 at 8:56 PM

$ARCT Cash of 191.5 million dollars at June 30 with no financial debt, and a stated runway to the end of 2028 — over two and a half years, as the company put it on August 6. Two Phase 2 programmes are running, and there were no ATM sales in the first half, so the share count is up just 0.03% since December 31. Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/arcturus-therapeutics-arct-stock-hub/?utm_source=stocktwits&utm_medium=social&utm_campaign=moderna-20ago2026

1 · Reply

STACKD0E Aug. 20 at 7:44 PM

$ARCT 🙃✨️

0 · Reply

MoneyMacG Aug. 20 at 7:13 PM

$INDI $CCXI $ARCT $ONFO $SNSC ;;

0 · Reply

1.0.0